PurposeThis study was designed to evaluate outcomes in women after hip arthroscopy (HA) for femoroacetabular impingement syndrome (FAIS) and compare these results with men.
MethodsRetrospective study of a prospective database of patients undergoing hip arthroscopy between 2015 and 2018. Inclusion criteria were patients between 18 and 50 years of age, diagnosis of FAIS, complete clinical patient‐reported outcomes (PROs), radiographic measurements, and underwent at least a 2‐year HA follow‐up. For each woman, two men underwent HA were matched in a 1:2 ratio based on age within 5 years, and date of surgery within 6 months. Diagnostic arthroscopy was performed to evaluate labral and chondral status. Radiographic evaluation, a self‐administered Hip Outcome Score (HOS) questionnaire, with activity of daily living (ADL) and sports subscale (SSS), and a self‐administered short version of the International Hip Outcome Tool (iHOT‐12) were assessed at 6 months, 12 months, and then yearly. Clinical relevance was measured with the minimal clinical important difference (MCID), patient acceptable symptom state (PASS), and substantial clinical benefit (SCB) for HOS‐ADL, HOS‐SSS, and iHOT‐12.
ResultsOne hundred and eighty‐five patients met the inclusion criteria. Fifty‐two women were matched with 104 men. Significant differences in terms of demographics, radiographic results, intraoperative findings and arthroscopic procedures were found between women and men. Mean follow‐up was 48.4 months in women and 50.2 months in men. Both groups showed significant improvement from preoperative PROs to the latest follow‐up. There were no significant differences between groups in preoperative PROs, latest follow‐up PROs and PROs improvements. The difference in frequency of patients achieving MCID, PASS, and SCB was only significant greater for iHOT‐12 PASS in women compared with men.
ConclusionSignificant improvements in PROs in women after HA for FAIS at 4‐year follow‐up were found. Differences between women and men in PROs and rates of achieving MCID, SCB and PASS were only significant for iHOT‐12 PASS.
Level of evidenceIV.
RESUMEN Objetivo: determinar la prevalencia y los factores preoperatorios asociados a la lesión del labrum acetabular en una serie única de pacientes intervenidos mediante cirugía artroscópica de cadera. Material y metodología: se realizó un estudio prospectivo de los hallazgos artroscópicos de 163 caderas, en 120 pacientes, con diagnóstico de choque femoroacetabular (CFA) intervenidos entre enero de 2012 y septiembre de 2016. Se determinó la prevalencia, la localización, la clasificación y los factores preoperatorios asociados a la lesión del labrum acetabular. Las lesiones del labrum acetabular se clasificaron según la clasificación propuesta por el grupo Multicenter Arthroscopic Hip Outcome Research Network (MAHORN). La edad media de los pacientes fue de 38 años y el grado de degeneración articular fue Tönnis 0, en 104 caderas, y Tönnis 1, en 59 caderas. Resultados: artroscópicamente, el tipo de CFA era mixto en 86 caderas (52,7%), de tipo Cam en 67 (41, 1%) y de tipo Pincer en 10 (6,2%). El labrum presentaba una morfología normal en 140 caderas (85,9%), era hipoplásico en 17 (9,8%) e hiperplásico en 6 (4,3%). Se detectó algún grado de rotura del labrum en 133 caderas (81,6%). La localización de las lesiones fue superior y anterior. Conclusión: en nuestro estudio no hemos encontrado factores preoperatorios del paciente que tengan relación con la presencia de lesión del labrum acetabular durante el procedimiento de la artroscopia de cadera. Nivel de evidencia: nivel IV. Palabras clave: Labrum acetabular. Artroscopia de cadera. Cadera. Choque femoroacetabular.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.